Movement Alert｜Akeso Rises 3.12% in Regular Trading, Innovative Drug Payment Reform Catalysts Continue After Prior Session Pullback

Market Focus07-08

On July 8, Akeso rose 3.12% in regular trading, trading at 99.75 HKD/share, with turnover of HKD 205 million. The stock rebounded following a 3.24% decline in the prior session when the broader biotech sector weakened.

On the news front, innovative drug payment reform continues to provide policy catalysts. All indications of Akeso's five self-developed new drugs have been included in China's national medical insurance program, and the company's new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. The broader policy backdrop includes the National Healthcare Security Administration's advancement of the dual medical insurance and commercial insurance directory negotiation process, alongside new mechanisms such as pre-declaration and 8-year price protection, providing a more stable policy outlook for innovative drug commercialization.

Within the Biotechnology sector, individual stocks showed mixed performance: SKB BIO down 5.18%, Remegen up 3.24%, Innovent Bio up 1.89%, BeiGene up 1.68%, Keymed Bio-B up 0.35%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114399715?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114399715","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Rises 3.12% in Regular Trading, Innovative Drug Payment Reform Catalysts Continue After Prior Session Pullback","media":"Market Focus","content":"<p><p>On July 8, Akeso rose 3.12% in regular trading, trading at 99.75 HKD/share, with turnover of HKD 205 million. The stock rebounded following a 3.24% decline in the prior session when the broader biotech sector weakened.</p><p>On the news front, innovative drug payment reform continues to provide policy catalysts. All indications of Akeso's five self-developed new drugs have been included in China's national medical insurance program, and the company's new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. The broader policy backdrop includes the National Healthcare Security Administration's advancement of the dual medical insurance and commercial insurance directory negotiation process, alongside new mechanisms such as pre-declaration and 8-year price protection, providing a more stable policy outlook for innovative drug commercialization.</p><p>Within the Biotechnology sector, individual stocks showed mixed performance: SKB BIO down 5.18%, Remegen up 3.24%, Innovent Bio up 1.89%, BeiGene up 1.68%, Keymed Bio-B up 0.35%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Rises 3.12% in Regular Trading, Innovative Drug Payment Reform Catalysts Continue After Prior Session Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Rises 3.12% in Regular Trading, Innovative Drug Payment Reform Catalysts Continue After Prior Session Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-08 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 8, Akeso rose 3.12% in regular trading, trading at 99.75 HKD/share, with turnover of HKD 205 million. The stock rebounded following a 3.24% decline in the prior session when the broader biotech sector weakened.</p><p>On the news front, innovative drug payment reform continues to provide policy catalysts. All indications of Akeso's five self-developed new drugs have been included in China's national medical insurance program, and the company's new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. The broader policy backdrop includes the National Healthcare Security Administration's advancement of the dual medical insurance and commercial insurance directory negotiation process, alongside new mechanisms such as pre-declaration and 8-year price protection, providing a more stable policy outlook for innovative drug commercialization.</p><p>Within the Biotechnology sector, individual stocks showed mixed performance: SKB BIO down 5.18%, Remegen up 3.24%, Innovent Bio up 1.89%, BeiGene up 1.68%, Keymed Bio-B up 0.35%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1114399715","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114399715","pubTimestamp":1783475372,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 8, Akeso rose 3.12% in regular trading, trading at 99.75 HKD/share, with turnover of HKD 205 million. The stock rebounded following a 3.24% decline in the prior session when the broader...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"异动快讯|康方生物常规盘涨3.12%前一交易日回调后创新药支付改革催化剂延续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 8, Akeso rose 3.12% in regular trading, trading at 99.75 HKD/share, with turnover of HKD 205 million. The stock rebounded following a 3.24% decline in the prior session when the broader biotech sector weakened.On the news front, innovative drug payment reform continues to provide policy catalysts. All indications of Akeso's five self-developed new drugs have been included in China's national medical insurance program, and the company's new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. The broader policy backdrop includes the National Healthcare Security Administration's advancement of the dual medical insurance and commercial insurance directory negotiation process, alongside new mechanisms such as pre-declaration and 8-year price protection, providing a more stable policy outlook for innovative drug commercialization.Within the Biotechnology sector, individual stocks showed mixed performance: SKB BIO down 5.18%, Remegen up 3.24%, Innovent Bio up 1.89%, BeiGene up 1.68%, Keymed Bio-B up 0.35%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114399715","isCrawlerRequest":true}